Additional Biologic Therapeutics

Erin E. Grinich; Eric L. Simpson

doi:10.1016/B978-0-323-61211-1.00031-0

Additional Biologic Therapeutics

Erin E. Grinich, Eric L. Simpson

Dermatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

2 Scopus citations

Abstract

Biologic therapy for atopic dermatitis and allergic conditions represents a rapidly developing area of research development and clinical investigation in dermatology. Dupilumab, a biologic that blocks both interleukin (IL)-4 and IL-13 signaling, is the first biologic approved by the Food and Drug Administration for the treatment of atopic dermatitis. Omalizumab, which binds free immunoglobulin (Ig)E, was first used to treat asthma and was subsequently approved for patients with refractory chronic idiopathic urticaria. In this chapter, dupilumab and omalizumab and their applications within dermatology are reviewed in detail. This chapter also highlights several emerging biologic therapeutics within the field of dermatology.

Original language	English (US)
Title of host publication	Comprehensive Dermatologic Drug Therapy, Fourth Edition
Publisher	Elsevier
Pages	339-348.e4
ISBN (Electronic)	9780323612111
ISBN (Print)	9780323612128
DOIs	https://doi.org/10.1016/B978-0-323-61211-1.00031-0
State	Published - Jan 1 2020

Keywords

IL-4 receptor
anaphylaxis
atopic dermatitis
chronic idiopathic urticaria
dupilumab
immunoglobulin E (IgE)
interleukin-13 (IL-13)
interleukin-4 (IL-4)
monoclonal antibody
omalizumab

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/B978-0-323-61211-1.00031-0

Cite this

@inbook{c0654226e1c04339bb9b3b0773da4be7,

title = "Additional Biologic Therapeutics",

abstract = "Biologic therapy for atopic dermatitis and allergic conditions represents a rapidly developing area of research development and clinical investigation in dermatology. Dupilumab, a biologic that blocks both interleukin (IL)-4 and IL-13 signaling, is the first biologic approved by the Food and Drug Administration for the treatment of atopic dermatitis. Omalizumab, which binds free immunoglobulin (Ig)E, was first used to treat asthma and was subsequently approved for patients with refractory chronic idiopathic urticaria. In this chapter, dupilumab and omalizumab and their applications within dermatology are reviewed in detail. This chapter also highlights several emerging biologic therapeutics within the field of dermatology.",

keywords = "IL-4 receptor, anaphylaxis, atopic dermatitis, chronic idiopathic urticaria, dupilumab, immunoglobulin E (IgE), interleukin-13 (IL-13), interleukin-4 (IL-4), monoclonal antibody, omalizumab",

author = "Grinich, {Erin E.} and Simpson, {Eric L.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-61211-1.00031-0",

language = "English (US)",

isbn = "9780323612128",

pages = "339--348.e4",

booktitle = "Comprehensive Dermatologic Drug Therapy, Fourth Edition",

publisher = "Elsevier",

}

TY - CHAP

T1 - Additional Biologic Therapeutics

AU - Grinich, Erin E.

AU - Simpson, Eric L.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Biologic therapy for atopic dermatitis and allergic conditions represents a rapidly developing area of research development and clinical investigation in dermatology. Dupilumab, a biologic that blocks both interleukin (IL)-4 and IL-13 signaling, is the first biologic approved by the Food and Drug Administration for the treatment of atopic dermatitis. Omalizumab, which binds free immunoglobulin (Ig)E, was first used to treat asthma and was subsequently approved for patients with refractory chronic idiopathic urticaria. In this chapter, dupilumab and omalizumab and their applications within dermatology are reviewed in detail. This chapter also highlights several emerging biologic therapeutics within the field of dermatology.

AB - Biologic therapy for atopic dermatitis and allergic conditions represents a rapidly developing area of research development and clinical investigation in dermatology. Dupilumab, a biologic that blocks both interleukin (IL)-4 and IL-13 signaling, is the first biologic approved by the Food and Drug Administration for the treatment of atopic dermatitis. Omalizumab, which binds free immunoglobulin (Ig)E, was first used to treat asthma and was subsequently approved for patients with refractory chronic idiopathic urticaria. In this chapter, dupilumab and omalizumab and their applications within dermatology are reviewed in detail. This chapter also highlights several emerging biologic therapeutics within the field of dermatology.

KW - IL-4 receptor

KW - anaphylaxis

KW - atopic dermatitis

KW - chronic idiopathic urticaria

KW - dupilumab

KW - immunoglobulin E (IgE)

KW - interleukin-13 (IL-13)

KW - interleukin-4 (IL-4)

KW - monoclonal antibody

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85107947866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107947866&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-61211-1.00031-0

DO - 10.1016/B978-0-323-61211-1.00031-0

M3 - Chapter

AN - SCOPUS:85107947866

SN - 9780323612128

SP - 339-348.e4

BT - Comprehensive Dermatologic Drug Therapy, Fourth Edition

PB - Elsevier

ER -

Additional Biologic Therapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this